Relapsed/Refractory Large B-cell Lymphoma Clinical Trial
Official title:
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
The primary objectives of this study are: Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2 Phase 2: To evaluate the efficacy of axicabtagene ciloleucel and utomilumab in participants with refractory large B-cell lymphoma
This study was intended to be a Phase 1/2, but the planned Phase 2 part has been canceled. After the study, participants who received an infusion of axicabtagene ciloleucel and utomilumab will complete the remainder of the 15-year follow-up assessments in a separate Long-term Follow-up study, KT-US-982-5968. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06079164 -
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT06414148 -
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
|
Phase 2 | |
| Terminated |
NCT04314843 -
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05800977 -
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
|
Phase 1/Phase 2 |